Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 2Thoracic 1Other solid neoplasm 1Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Ovarian Neoplasms 12Fallopian Tube Neoplasms 6Breast Neoplasms 6Endometrial Neoplasms 4Prostatic Neoplasms 3Pancreatic Neoplasms 3Triple Negative Breast Neoplasms 2Stomach Neoplasms 2Small Cell Lung Carcinoma 2Carcinoma, Ovarian Epithelial 2Carcinoma, Non-Small-Cell Lung 2Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma, Ewing 1Recurrence 1Neoplasm Metastasis 1Mesothelioma 1Fanconi Anemia, Complementation Group D1 1Colorectal Neoplasms 1Advanced Ovarian Cancer 1

Interventions

pembrolizumab 35Paclitaxel 10Nivolumab 10Carboplatin 9atezolizumab 7Docetaxel 7Cisplatin 7Ipilimumab 5Gemcitabine 5Cyclophosphamide 5spartalizumab 4fludarabine 4Fluorouracil 4lenvatinib 3durvalumab 3cemiplimab 3avelumab 3Vorinostat 3Trastuzumab 3Oxaliplatin 3Leucovorin 3Immunoglobulin G 3Fulvestrant 3Cetuximab 3Bevacizumab 3zimberelimab 2tisotumab vedotin 2tislelizumab 2sargramostim 2aldesleukin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Squamous Cell Carcinoma of Head and Neck × talazoparib × Gynecologic × Clear all
NCT02567396 2017-04-24

Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney Dysfunction

National Cancer Institute (NCI)

Phase 1 Withdrawn
BreastGastrointestinalGynecologicHead & NeckOther solid neoplasmThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Mesothelioma, Ovarian Neoplasms, Stomach Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡